TBL-100 / TauC3 Bio, LifeArc - LARVOL DELTA

Drug Development. (PubMed, Alzheimers Dement) - "TBL-100 has exquisite end specificity for tau cleaved at Asp421 (tauC3). It bound oligomeric tauC3 with the same high affinity as it bound monomeric tauC3, supporting TBL-100's potential to interrupt oligomer-driven spreading of pathology. TBL-100's high affinity and specificity for pathogenic tau support its development as a treatment for tauopathies."

Journal

Outcomes and Effects of 250-cm Biliopancreatic Limb One Anastomosis Gastric Bypass in Patients with BMI > 50 kg/m with Total Bowel Length > 6 m: a 2-Year Follow-up. (PubMed, Obes Surg) - "Long BP (250 cm) OAGB in patients with BMI > 50 kg/m with TWL > 6 m had good results in the achievement of weight loss and weight maintenance goals with remission of associated comorbidities as HTN and DM."

Journal • Hypertension

TAU BIO-LOGIC announces humanization of picomolar affinity monoclonal antibody targeting TauC3 protein for the treatment of Alzheimer's disease and progressive supranuclear palsy (PRNewswire) - "TAU BIO-LOGIC CORP. announced today that in collaboration with the UK-based group LifeArc, it has successfully humanized a monoclonal antibody (TBL-100) that targets C-terminally truncated tau (tauC3). TAU BIO-LOGIC is developing TBL-100 for the treatment of Alzheimer's disease (AD) and Progressive Supranuclear Palsy (PSP)....In AD, tauC3 is formed early in the disease course and levels correlate with cognitive decline. TauC3 causes intracellular neurotoxicity and is also believed to be the major driver of tau propagation. A study conducted by Professor Bradley Hyman...demonstrated TBL-100's potential to block tau propagation in the AD brain."

Licensing / partnership

Newly added product (PRNewswire) - Preclinical, Alzheimer's Disease

Pipeline update